Dustin Samples

Cancer Nursing Today nonprod

Nurses must be aware of cytogenetic testing outcomes and gene-mutation profiles in patients with multiple myeloma (MM), insists a recent study published in the Clinical Journal of Oncology Nursing (CJON).Cytogenetics is the study of chromosomal abnormalities and their effect on cell behavior. Chromosomal abnormalities in the bone marrow can say quite a bit about the expected course of disease.Using fluorescence in situ hybridization (FISH), one cytogenic assessment technique, clinicians and laboratory analysts can stratify patients into disease-risk levels.&ldquo;Patients with standard risk have the presence of chromosomal abnormalities t(11;14), t(6;14), or hyperdiploidy, whereas those with intermediate risk have the presence of t(4;14), del 13, or hypodiploidy, and those with high risk have the presence of del 17p, t(14;16), or t(14;20),&rdquo; explains Donna Catamero, ANP-BC, OCN&reg;, CCRC, author of the CJON study.&ldquo;Cytogenetic abnormalities in MM influence every aspect of the disease, including progression from [monoclonal gammopathy of undetermined significance], a benign condition, to MM, as well as a patient&rsquo;s risk of relapse and his or her clinical presentation.&rdquo;Bone marrow biopsies can also predict response to treatment.Because of the frequency of bone marrow biopsy in patients with MM or related disease, nurses should familiarize themselves with gene mutations and other cytogenetic testing results.&ldquo;Oncology nurses need to understand the science and meaning of bone marrow biopsy reports,&rdquo; Donna implores, &ldquo;including the implications of genetic alterations and minimal residual disease. This will allow them to provide care, support, and education related to MM and its treatment to patients and their families.&rdquo;<h3>Reference</h3><a href="https://store.ons.org/cjon/22/3/multiple-myeloma-detecting-genetic-changes-through-bone-marrow-biopsy-and-influence-care" target="_blank" rel="noopener">Multiple myeloma: detecting genetic changes through bone marrow biopsy and the influence on care</a>

Cytogenetics Offers Insight Into MM Disease Course, Risk, and Outcomes

Multiple Myeloma

Fluorescence in situ hybridization can detect genetic abnormalities that allow stratification of disease risk. 

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe